Growth hormone secretagogue names a category by what a compound targets. The word secretagogue means something that prompts a cell to release a substance, so the label says where the molecule acts and leaves everything else open.
The receptor was found before its natural signal
The usual order in pharmacology is that a hormone is identified and its receptor found afterwards. This class ran the other way. Synthetic compounds that triggered growth hormone release were known first, and the receptor they acted on was identified in 1996 and named after them: the growth hormone secretagogue receptor. (Reference: Howard et al., 1996)
It remained an orphan receptor until 1999, when its endogenous ligand, ghrelin, was identified. (Reference: Kojima et al., 1999) That history is why the same receptor carries two names in the literature, and why a compound in this class is described both as a growth hormone secretagogue and as a ghrelin receptor agonist. Both are correct.
The natural ligand carries a fatty acid
Ghrelin has a feature that is unusual among peptide hormones: a fatty acid attached to one of its residues, added by a dedicated enzyme. The unmodified peptide does not activate the receptor the way the modified one does. (Reference: Kojima et al., 1999)
The detail is worth knowing when comparing compounds, because a synthetic secretagogue does not need to imitate that modification to reach the same receptor. Several of them are small peptides with no fatty acid at all.
Why an orphan receptor is a useful thing to find
A receptor identified before anyone knows what binds to it naturally is called an orphan. Finding one poses an immediate question, since a receptor that exists is presumably responding to something, and the search for that something is a well-defined project with a clear endpoint.
The synthetic compounds that led to the receptor kept their usefulness afterwards. A molecule that activates a receptor is a tool for asking what that receptor does, independently of whether it resembles the natural ligand, and the compounds in this class were being used that way for years before ghrelin was found.
Upstream is doing work in that sentence
Describing a receptor as sitting upstream of a pathway says the signal passes through several steps before anything measurable happens at the other end. Each of those steps is a place where something else can intervene, and where the state of the system decides how much of the signal gets through.
Observations from these compounds depend on the model they were made in. A result from cultured cells and a result from an intact animal are answering related but different questions, and neither transfers automatically to the other.
The class is chemically mixed
Membership is defined by the target, not by structure, so the compounds grouped under this label have little in common as molecules. Some are short peptides, some are peptide-like, and some are not peptides. Our note on ipamorelin covers a pentapeptide in the class whose five residues include units no organism builds.
The consequence for reading a catalogue is that the label predicts nothing about the material: not the size, not the stability, not what the synthesis or the analysis required.
What selective means here
Earlier compounds in the class engaged their target and also touched other hormone axes. Selectivity, in this context, describes a compound that acts on its target pathway with limited activity elsewhere, and ipamorelin was characterised as the first with that profile. (Reference: Raun et al., 1998)
For a research tool the value of a clean profile is interpretive. The fewer pathways a compound touches, the fewer alternative explanations there are for an observation. Selectivity is always a comparison under stated conditions, never an absolute, which our note on agonists and antagonists covers alongside why two papers can report different figures for one compound.
These are preclinical, model-based observations. Compounds in this class are supplied strictly as research compounds, and nothing here describes use in people or animals.
Secretagogue is not the same as the hormone
A distinction worth stating plainly, because the category name invites the confusion. A secretagogue is not growth hormone. It is a separate molecule studied for its action on a receptor that sits upstream of that pathway, and growth hormone itself is a protein of around two hundred residues, an entirely different kind of material to make and to verify.
Our note on amino acids, peptides and proteins covers why that size difference changes everything about handling.
What the label says about a vial
Nothing. It places a molecule in a category based on published work about its target. The category is drawn from published pharmacology, not from anything measured in the vial. Whether a batch contains that molecule, and what share of the powder it represents, comes from a purity measurement by HPLC and an identity measurement by mass spectrometry.
For short peptides in this class the identity question carries a specific wrinkle: several contain D-configured residues, and a D residue has exactly the same mass as its L counterpart. Mass alone cannot catch that substitution, which is one more reason purity and identity are reported together on a certificate that names your batch, and you can look that number up.
Where a specification names a D residue explicitly, it is naming something the supplier has to have controlled during synthesis, since the correct isomer has to be used at that position in the first place.
Research use only
This article is background pharmacology for laboratory context. All products sold by Codex Research are strictly for research and development, are not for human or animal consumption, and are not intended to diagnose, treat, cure, or prevent any disease.
These compounds in the catalog
Frequently asked questions
What is a growth hormone secretagogue?
A compound studied for its action on the receptor that sits upstream of growth hormone release. A secretagogue is anything that prompts a cell to release a substance, so the label names the target rather than a structure or an effect.
Is the ghrelin receptor the same as the growth hormone secretagogue receptor?
Yes. The receptor was identified in 1996 through the synthetic compounds that acted on it and named after them. Its natural ligand, ghrelin, was identified in 1999, which is why the same receptor carries both names.
What is unusual about ghrelin itself?
It carries a fatty acid attached to one of its residues, added by a dedicated enzyme, and the unmodified peptide does not activate the receptor the way the modified one does. Synthetic secretagogues do not need that modification to reach the same receptor.
Do compounds in this class resemble each other?
Not necessarily. Membership is defined by the target, so the group includes short peptides, peptide-like molecules and compounds that are not peptides at all. The label predicts nothing about size, stability or how the material was made.
What does selective mean for a secretagogue?
That the compound acts on its target pathway with limited activity at other hormone axes that earlier compounds also affected. It is a comparison under stated conditions, not an absolute property.
Is a secretagogue the same as growth hormone?
No. Growth hormone is a protein of around two hundred residues. A secretagogue is a separate and usually much smaller molecule studied for its action on a receptor upstream of that pathway.
References
- Howard, A.D., et al. (1996). A receptor in pituitary and hypothalamus that functions in growth hormone release. Science, 273(5277), 974-977.
- Kojima, M., et al. (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 402, 656-660.
- Raun, K., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561.
- Kenakin, T. (2004). Principles: receptor theory in pharmacology. Trends in Pharmacological Sciences, 25(4), 186-192.